Dr. Morrison is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Elm and Carlton Streets
Buffalo, NY 14263Phone+1 716-845-2906- Is this information wrong?
Summary
- As a board-certified pathologist with interests in both surgical and molecular pathology I regularly participate in the sign out of surgical pathology reports and advanced diagnostic laboratory tests. From a surgical pathology perspective my interest has always been in bone and soft tissue. As a molecular pathologist my interest has extended past single analyte tests to advanced diagnostic testing with an emphasis on next generation sequencing. More recently have focused on the application of this technology in the immune-oncology space with the development of cutting edge assays to predict response to checkpoint inhibitors and guide choice of combination immunotherapy (i.e. precision immunotherapy). On a national basis, as the founder of OmniSeq Inc as a national provider of genomic and immune-related advanced diagnostic assays. Routinely speak at immunotherapy conferences about prediction of response to checkpoint inhibitors and guide choice of combination immunotherapy.
Education & Training
Ohio State University HospitalResidency, Pathology-Anatomic and Clinical, 1998 - 2002
University of Kentucky College of MedicineClass of 1998
Certifications & Licensure
NY State Medical License 2006 - 2026
MD State Medical License 2017 - 2021
OH State Medical License 2001 - 2008- American Board of Pathology Anatomic Pathology
Awards, Honors, & Recognition
- Tomasi Award Roswell Park, 2015
Publications & Presentations
PubMed
- 1 citationsDevelopment and implementation of an automated and highly accurate reporting process for NGS-based clonality testing.Sean T Glenn, Phillip M Galbo Jr, Jesse D Luce, Kiersten Marie Miles, Prashant K Singh, Manuel J Glynias, Carl Morrison> ;Oncotarget. 2023 May 12
- 26 citationsMetabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses.Kunle Odunsi, Feng Qian, Amit A Lugade, Han Yu, Melissa A Geller, Steven P Fling, Judith C Kaiser, Andreanne M Lacroix, Leonard D'Amico, Nirasha Ramchurren, Chihiro Mo...> ;Science Translational Medicine. 2022 Mar 16
- 66 citationsT-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitorsTakayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, Vaibhav Jain, Hongbin Chen, Kristopher Attwood, Sebastiano Battaglia, Saby George, Gurkamal Chatta, Igor Puzanov, Carl...> ;Nature Communications. 2021 Mar 3
- Join now to see all
Press Mentions
Roswell Park Licenses Rapid, Comprehensive Blood Test to Agilent, a Global Leader in the Life Sciences MarketOctober 20th, 2023
Hospital Affiliations
Roswell Park Comprehensive Cancer CenterBuffalo, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
